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Abstract
Cancer is sometimes depicted as a reversion to single cell behavior in cells adapted to live
in a multicellular assembly. If this is the case, one would expect that mutation in cancer dis-
rupts functional mechanisms that suppress cell-level traits detrimental to multicellularity.
Such mechanisms should have evolved with or after the emergence of multicellularity. This
leads to two related, but distinct hypotheses: 1) Somatic mutations in cancer will occur in
genes that are younger than the emergence of multicellularity (1000 million years [MY]); and
2) genes that are frequently mutated in cancer and whose mutations are functionally impor-
tant for the emergence of the cancer phenotype evolved within the past 1000 million years,
and thus would exhibit an age distribution that is skewed to younger genes. In order to inves-
tigate these hypotheses we estimated the evolutionary ages of all human genes and then
studied the probability of mutation and their biological function in relation to their age and
genomic location for both normal germline and cancer contexts. We observed that under a
model of uniform random mutation across the genome, controlled for gene size, genes less
than 500 MY were more frequently mutated in both cases. Paradoxically, causal genes,
defined in the COSMIC Cancer Gene Census, were depleted in this age group. When we
used functional enrichment analysis to explain this unexpected result we discovered that
COSMIC genes with recessive disease phenotypes were enriched for DNA repair and cell
cycle control. The non-mutated genes in these pathways are orthologous to those underly-
ing stress-induced mutation in bacteria, which results in the clustering of single nucleotide
variations. COSMIC genes were less common in regions where the probability of observing
mutational clusters is high, although they are approximately 2-fold more likely to harbor
mutational clusters compared to other human genes. Our results suggest this ancient muta-
tional response to stress that evolved among prokaryotes was co-opted to maintain diversity
in the germline and immune system, while the original phenotype is restored in cancer.
Reversion to a stress-induced mutational response is a hallmark of cancer that allows for
effectively searching “protected” genome space where genes causally implicated in cancer
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are located and underlies the high adaptive potential and concomitant therapeutic resis-
tance that is characteristic of cancer.
Introduction
A defining quality of life is its phenotypic plasticity, generated through the ability to regulate
gene expression and other cellular functions in response to environmental factors, critical
properties that enable organisms to respond to a wide variety of environmental challenges in a
coordinated and systematic way [1–4]. Yet when confronted with persistent unfavorable con-
ditions, primitive life forms could exhibit more dramatic and evolutionarily deep-rooted
responses. In these circumstances, a population of microorganisms is likely to face extinction
unless an appropriate adaptation is promptly deployed. A prime example of an adaptive strat-
egy is for cells to elevate their rate of genetic mutation in order to increase the probability of
discovering a solution to their burden. Mechanisms such as slipped-strand mispairing, poly-
merase slippage, gene amplification, deregulation of mismatch repair, and recombination
between imprecise homologies underlie the generation of genetic alterations at high frequen-
cies under specific conditions [5–7]. These genotypic alterations can promote phenotypic het-
erogeneity and adaptive potential in clonal populations of cells, even during stationary growth
phases, a process that has been termed “adaptive mutation” [7–14]. Such mechanisms allow
for heightened exploration of the phenotypic landscape during conditions of stress, leading to
higher rates of effective evolution; a condition well illustrated with the popular proverb:
“necessity is the mother of invention”.
Cancer is a disease of bodies, and therefore of multicellular organisms, yet many of the hall-
marks of cancer [15,16] suggest an atavistic reversion to an ancestral single-celled phenotype.
For cancer cells, the body is no longer a larger functioning organism to which they belong and
support, but a complex host ecosystem that they adapt to in order to survive and thrive. From
a theoretical standpoint, the emergence of multicellularity represents an increase in the com-
plexity of life in which cells became cooperative aggregates because of the balance between cel-
lular conflict and collective fitness. This transition requires the evolution of both cooperation-
promoting and conflict-reducing adaptations [17]. While the mechanisms for adaptive muta-
tion are essential for the survival of single celled organisms exposed to stress, somatic cells in
multicellular organisms typically reside in stable homeostatic conditions and are thus “pro-
tected” from the drastic changes in the environment that demand engaging in such heritable
responses. Furthermore, the integrity of the multicellular structure demands global genetic
coherence and strong inhibition of independent somatic cell evolution, although phenotypic
plasticity, sometimes heritable, is required in order to maintain function in the face of organ-
ism level stresses that place large, differential demands on organs [18,19]. It is well known that
genes associated with cancer have phylogenetic origins associated with the emergence of
multicellularity [20–23]. For example, the genomic analysis by Domazet-Losˇo and Tautz [21]
based on four different cancer gene datasets demonstrated that the origin of gatekeeper onco-
genes coincides with a pronounced phylostratigraphic peak at the onset of Metazoa. It there-
fore seems plausible that a source of stress capable of breaking the homeostatic equilibrium in
the milieu could trigger an ancestral adaptive mutation program in a somatic cell, inducing
genetic instability that could result in cancer if not suppressed by other mechanisms. In this
context cancer can be understood as a relaxation of the genetic constraints evolved to maintain
Stress-induced mutation in cancer
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the complex structure of multi-cellularity, resulting in a relaxation of constraints that suppress
individual somatic cell evolution[20–24].
Here we present evidence demonstrating that cancer manifests as an atavistic recapitulation
of pre-metazoan [24] mechanisms of stress-induced mutation in somatic cells, explaining its
capacity to evolve resistance to therapy. The mechanistic roots of this behavior are retained
over evolutionary time scales because they are critical to the successful function of the germline
and immune system. In addition to generating base-line diversity in both the innate and adap-
tive immune system, normal germline mutational patterns maintain diversity in recently
evolved gene families governing functions such as toxin detection and detoxification. In cancer
the controlled restriction of this phenomenon to the germline and immune system is dis-
rupted, allowing somatic cells to effectively search ancient genome space for solutions to the
stress-induced pressures they are experiencing. We propose stressed-induced mutation as a
hallmark of cancer reflected by genomic instability.
Methods
Gene ageing
Gene homologies represent the evolutionary history of gene families. Accordingly, an ortholog
of a human gene found in any other species can be assumed to have diverged from a common
ancestor. Thus, by grouping orthologous genes into gene families, the age of the human gene
can be identified by the divergence time of the last common ancestor of all the species con-
tained within the gene family.
Given that this approach is contingent on the definition of homology, more accurate gene
family builds will lead to better estimations of gene ages. We looked at three pertinent homol-
ogy databases to identify the one with the most coverage across all kingdoms of life and the
most robust human gene families. We considered Ensembl Compara / Ensembl Pan-Taxo-
nomic Compara [25,26] (release 22, containing 19,756 genes), NCBI HomoloGene [27]
(18,304 genes) and HOGENOM [28] (17,086 genes from the nucleotide database). We chose
these databases because they cover many species across all taxonomic groups and use both pro-
tein and genetic sequence comparisons with sophisticated phylogenetic reconciliation meth-
ods to predict evolutionary trees across the whole set of protein-coding genes and non-coding
RNA (ncRNA) genes [26]. Based on our analysis (see S1 Text for details) we selected the
Ensembl Compara/Ensembl Pan-Taxonomic Compara database as the best option for generat-
ing gene families in our ageing method.
We then determined gene ages as the maximum phylogenetic divergence time between
humans and all the species represented in each corresponding gene family according to the
TimeTree database [29]. The age of a common ancestor in an evolutionary tree is always older
than the divergence time between all the species branching out from it, therefore this measure
provides an estimate of the minimum expected age of the gene.
Cancer gene list
Sanger’s Catalogue Of Somatic Mutations In Cancer (COSMIC) is a comprehensive resource
of somatic mutations in human cancer [30,31]. We studied 458 genes with mutations that have
been causally implicated in cancer (Cancer Gene Census), and categorized each as dominant,
recessive, or both according to COSMIC annotations. This classification is based on whether a
single allele (dominant) or multiple alleles (recessive) must be mutated in order to observe a
cancer phenotype.
Stress-induced mutation in cancer
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Genomic analysis
We obtained variants called from whole genome sequence (WGS) samples from the Interna-
tional Cancer Genomics Consortium (ICGC) data portal [32] (release 19) for a total of 764
samples from a variety of tissues, including: pancreas (262), prostate (198), ovarian (115), bone
(97), skin (59), blood (26), brain (4) and 3 samples with unknown tissue of origin (see Table C
in S1 Text for a list of references per project and S4 Table for a list of specific donors and sam-
ples). We also obtained normal tissue variants data from the Complete Genomics Indices data-
base in the 1000 Genome Project [33] (release 20130502, see S4 Table for list of donors). In
this case, we mined 129 WGS trio samples to identify private variations (i.e. present in the
donor but not in either parent). We parsed this data to identify the genomic locations of both
double strand break (DSB) events comprising complex multi-base variations, section dele-
tions/insertions and other DNA rearrangements and single nucleotide variants (SNV) repre-
senting deletions, insertions, and substitutions of one or two bases. Alterations in regions
containing single-, di-, and tri-nucleotide repeats where strand slippage could account for
larger rearrangements were also classified as SNVs.
A priori, we removed all events occurring in regions known to be involved in somatic
hypermutation [34,35] to avoid biasing the clustering analysis. A group of SNVs were deter-
mined to be in a cluster if the distance between two SNVs was less than 25 kb, the cluster had
at least 3 SNVs, and the probability of finding such a grouping of SNVs by chance was less
than 1% [35]. Hotspotting of clusters was determined by evaluating the number cluster centers
observed inside intervals of 1 kb across each chromosome. The expected value of events in the
interval was given by the total number of events divided by the number of intervals in the chro-
mosome. Using a binomial test we determined if the observed number of events was larger,
smaller, or close to the statistically expected value based on a uniform distribution of events,
defining the interval as a hot, cold, or null region, respectively. Odds ratios were computed
using a Fisher’s Exact test as implemented in the fisher.test function in R.
Functional enrichment analysis
We used the Functional Enrichment clustering tool of DAVID [36,37] to determine cellular
functions over-represented in various gene lists. This tool evaluates gene sets for enrichment
across multiple ontologies and then groups the resulting enriched functions into clusters
defined by maximizing the overlap of gene membership within the enriched functions. We
designated genes by their Ensembl ID and enrichment using all human genes as the back-
ground list for comparison unless otherwise specified. The default ontologies and stringency
settings were used for all analyses. We reported functional enrichment if the Benjamini-Hock-
enburg [38] corrected p-value was less than 0.05 for 3 or more categories within a cluster.
Results
Mutational frequency of human genes as a function of evolutionary age
The atavistic model of cancer presumes that the cancer phenotype is to some degree an evolu-
tionarily conserved ‘genetic subroutine’ that is suppressed by multicellularity but becomes re-
activated through oncogenic progression [24,39]. There are two related, but distinct hypothe-
ses that result from this model: 1) Somatic mutation will avoid regions of the genome with
deep-evolutionary roots, and thus occur in genes that are younger than the emergence of
multicellularity (1000 million years [MY]); and 2) genes that are frequently mutated in cancer
and whose mutations trigger the cancer subroutine evolved between 500–1000 MYA or with
Stress-induced mutation in cancer
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the evolution of complex multicellularity (<500 MYA), and thus would exhibit an age distri-
bution that is skewed to younger genes.
We tested the first hypothesis by establishing the evolutionary ages of 19,756 human genes
by assigning them to gene families according to the Ensembl Compara homology database.
We then defined the age of the human member of the gene family as the maximum phyloge-
netic divergence time between humans and the species represented in the corresponding gene
family. Next we examined mutational frequencies as a function of the evolutionary age of each
gene in both normal tissue (“normal”) and cancer. In normal tissue, we analyzed the private
SNVs from 129 individuals derived from 1000 Genomes Project whole genome sequencing
trio data [33]. Under the null model of uniform, random mutation, the frequency of mutation
for a given gene is dependent on the length of the gene such that we expect longer genes to
accumulate more mutations. When we look strictly at mutational frequency relative to evolu-
tionary age, genes less than 500 MY old were mutated less frequently compared to other age
groups (Table A in S1 Text, S2A Fig). Interestingly, when we considered the length of genes
relative to their evolutionary ages, genes younger than 500 MY were shorter on average com-
pared to all other age groups (S2C Fig). We controlled for this observation by determining the
expected number of mutations per base-pair and then calculated the ratio of observed to
expected number of mutations in each gene, generating a fold-change enrichment score.
Fig 1A and S2D Fig demonstrate that for their size, genes younger than 500 MY were more
likely to be mutated. In addition mutations in genes were 10% less frequent than mutations
outside of genes.
We then addressed whether a similar pattern exists in cancer. We looked at 764 samples
from of the ICGC (release 19) that had whole genome sequencing with calls for both simple
somatic mutations and structural mutations. Under the same null model assumption, genes in
cancer cells had 15% less mutation compared to non-gene regions of the genome. Thus cancer
recapitulates the pattern seen in normal tissue: mutation occurs predominantly outside of
Fig 1. Younger genes are mutated more frequently in both normal and cancer. The Enrichment Ratio is the observed rate of
mutation of a gene (in mutations per base-pair) over the expected value according to the null hypothesis of uniform random mutations.
We categorized genes in three main age groups, corresponding to post-metazoan (less than 500 MY), metazoan (between 500 and
1000 MY) and pre-metazoan (more than 1000 MY) ages and produced the distribution of Enrichment Ratio for each group. Genes
younger than 500 MY old are mutated significantly more frequently in both normal (A) and cancer (B). Also, the frequency of mutation
declines as the age of the gene increases. P-values in each case are taken as the maximum between the p-value given by a Tukey’s
range test between the three groups and a pair-wise t-test comparison.
https://doi.org/10.1371/journal.pone.0176258.g001
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genes, and mutation that occurs within genes is more frequent in genes younger than 500 MY
(Table A in S1 Text, S2E Fig).
We also examined the patterns of mutation in cancer relative to what was observed in the
normal tissue, which is equivalent to a non-uniform but random distribution in the genome,
as shown in Fig 2. We observed that relative to normal, the overabundance of mutation in
genes<500 MY becomes even more prominent, while genes older than 1000 MY are typically
not over-mutated. The mean age of over-mutated genes is significantly lower than the mean
age of all the genes, hence confirming the first hypothesis. Looking in greater detail at the
<500 MY age group, we found that cancer indeed appears to profoundly dysregulate muta-
tional processes in genes younger than 500 MY. A greater number of genes in this age group
Fig 2. Cancer displays a distinct mutational pattern relative to normal based on the evolutionary age of genes. For each human
gene, the expected number of mutations is obtained based on the normal mutation pattern: frequency of normal mutations times the total
number of cancer mutations recorded in the data set. According to this, the Enrichment Ratio (ER) is calculated as the ratio of observed
cancer mutations and the number of expected mutations in the gene. Over-mutated genes have ER > 1.5; under mutated genes have ER
< -1.5. Numbers in legend indicate the size of each gene set. Cross marks (X) on bars tips indicate the enrichment in that category is
statistically significant at p < 0.01 according to a bootstrap test taking random samples from the set of all human genes (BSQ < 1%, see
Table 1). Boxplots in lower panel show distribution quartiles; black vertical lines are medians, yellow diamonds are means and black dots
are outliers.
https://doi.org/10.1371/journal.pone.0176258.g002
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have either more or less than the expected number of mutations (S3 Fig). These results suggest
somatic mutation in cancer is preferentially occurring in evolutionarily young genes. But does
this mean that genes that drive cancer are evolutionarily young?
To test the second hypothesis that genes that are both frequently and causally mutated in
cancer are evolutionarily younger than the emergence of multicellularity as a whole (<1000
MY), we evaluated the evolutionary ages of genes demonstrated to be causally mutated in can-
cer as compiled by COSMIC in the Cancer Gene Census [31]. In contrast to the model predic-
tion, the general properties of the age distribution of the COSMIC genes did not differ
significantly from those of all other human genes (Fig 3A), e.g. as a sample it is representative
of the age distribution of all human genes. However, it is clear that there are sub-grouping dif-
ferences between the two distributions (Table 1). The COSMIC list is enriched with genes hav-
ing ages that correspond to the development of multicellularity (500–1000 MY), as has been
reported previously [20,21], and supports the idea that cancer is at least partially driven by dis-
ruption of functions that evolved to achieve multicellular organization. It must be mentioned
that this result is also true for the list of genes implicated in single-gene Mendelian disorders
(drawn from the Online Mendelian Inheritance in Man OMIM, Fig 3B), suggesting that this is
not a feature peculiar to cancer, except perhaps the overrepresentation of genes that evolved
with early multicellularity (1000–1500 MY). Interestingly, even though young genes are more
likely to be mutated in cancer and normal tissues, both the COSMIC and the OMIM lists are
depleted in genes with ages younger than 500 million years (Fig 3).
COSMIC contains 458 genes with different mutational modes of action: those that yield
dominant phenotypes and therefore require a single mutant allele (343), and those that give
Fig 3. Genes causally implicated in cancer are under-represented among young (<500 MY) genes. (A) Age distribution of
dominant (green) and recessive (orange) genes from COSMIC Cancer Gene Census. Grey bars represent the age distribution of all
human genes in ENSEMBL, and blue the age distribution of all COSMIC genes. Numbers in legend are the sizes of each gene set. Cross
marks (X) on bars tips indicate the enrichment in that category is statistically significant according to Gene Enrichment Score method and
a bootstrap test (BSQ < 1%, see Table 1). Accordingly, the second hypothesis predicts that the blue bars should skew to the left with
enrichment in both <500 MY and 500–1000 MY. This is not observed. The under-representation of very young genes (less than 500 MY)
and the over representation of dominant genes between 500 and 1500 MY are statistically significant. The distinct right skew of the
recessive set is also statistically significant (t-test for the difference of the mean with all other sets has p<0.01). This implies that
recessive genes are older than expected from random sampling. (B) Similar age distributions for single-gene Mendelian disorders, from
the Online Mendelian Inheritance in Man database (OMIM). The general pattern in gene age distributions between dominant and
recessive phenotypes observed in cancer, particularly the recessive gene skewness towards old ages and the under-representation of
very young genes, is replicated in these gene sets. No notable overrepresentation of dominant genes at moderate ages is detected in
this case. The enrichment of cancer genes in such age range is likely associated to breakdown of regulation functions that evolved during
the emergence of multicellularity.
https://doi.org/10.1371/journal.pone.0176258.g003
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recessive phenotypes (101), requiring that all alleles within the cell be altered. Twelve genes in
this list have no clearly defined molecular genetics. It should be noted that the set of dominant
genes overlap to a large degree with oncogenes (260 out of 264 genes considered oncogenes
[30,40] are dominant), while tumor suppressor genes overlap with recessive genes (70 out of
72 tumor suppressor genes are recessive). However, more than a quarter (122) of the genes in
the Cancer Gene Census cannot be classified as either oncogenes or tumor suppressors,
although they can still be classified according to their phenotypic expression (dominant or
recessive). We observed that the genes with recessive mutations were significantly older rela-
tive to all human genes (Fig 3A, Table 1), while genes with dominant mutations were overrep-
resented at ages that correspond with the emergence of multicellularity. In this respect, cancer
resembles single-gene Mendelian disorders (Fig 3B), which also display a difference in the ages
of genes with dominant or recessive phenotypes.
Ancient recessive genes are enriched for DNA repair and cell cycle
control
The paradox of cancer-causing genes being under-represented in the age bin with the highest
frequency of mutation suggests there may be an underlying mechanism that explains the shift
in mutational frequency revealed by determining the functions of the dominant versus reces-
sive genes. Functional annotation and enrichment analysis of COSMIC genes using DAVID
[36,37] with all human genes as the background list revealed that COSMIC genes with domi-
nant mutations were enriched for transcription factors and transcriptional regulation, immune
system development, receptor tyrosine kinases and signal transduction, “stem”-ness and mor-
phogenesis. COSMIC genes with recessive phenotypes were enriched for functions related to
DNA repair and cell cycle control (Fig 4); genes with ages older than 950 million years drove
such enrichment. The result is so striking that it persists irrespective of the background list
used for comparison (recessive cancer genes, all cancer genes, or all human genes). The genes
with recessive phenotypes involved in DNA repair focused particularly on double-strand
break (DSB) repair and nucleotide excision repair mechanisms. Looking at the evolutionary
history of the genes involved in these processes we noted that the non-mutated genes in the
same DNA repair pathways, such as REV1, REV3L, POLK, POLH, POLI, POLD1, DMC1, and
POLDIP2, are orthologous to genes in bacteria that underlie the adaptive mutation response
to stress [7,10,42,43] (see S5 Table for full list of human orthologs). The initiation of the SOS
response following the sensing of a double strand break leads to an increase in the rate of both
single base-pair mutations and gene amplification events near the DSB as the bacteria switch
from high-fidelity replication and repair to error-prone repair. This made us wonder if a simi-
lar mechanism was implicated in the patterns of mutations observed cancer.
Cancers exhibit a molecular signature of stress-induced mutagenesis
In bacteria, the process of adaptive mutation results in a molecular fingerprint in the form of a
cluster of SNVs around each DSB[44]. If cancer involves an analogous process, might we find
a similar signature? SNV clusters have indeed been reported in cancer[35], but reports thus far
fail to consider evolutionary history or genomic distribution relative to a model of uniform,
random mutation. This is important because the presence or absence of clusters may be con-
strained by the interplay between genomic evolution and selection at both organismal and cel-
lular levels.
To address these shortcomings, we used whole genome sequencing data (ICGC release 19)
that showed evidence for DSBs. We then evaluated whether or not SNVs clustered in each
sample. Out of 764 tumor samples from seven different sites (pancreas, prostate, bone, ovary,
Stress-induced mutation in cancer
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skin, blood, and brain), 668 (87.4%) had evidence of SNV clustering. These clusters do not
necessarily represent kataegis, defined as 6 or more mutations with inter-mutational distance
of 1kb or less [45], but our definition of clustering would catch kataegis events. To evaluate
whether the clustering is a peculiarity of somatic mutation in cancer or represents a fundamen-
tal process underlying mutation generally, we performed the same analysis on the normal data
from 1000 Genomes as a control. Surprisingly, all of the normal samples also had evidence of
clustering of SNVs.
We observed a distinctive difference in the non-random spatial distribution of clusters
across the genome in both normal and cancer (Fig 5, S4–S6 Figs), suggestive of “hotspotting”
of clusters when considered across samples, e.g. regions of the genome where clusters are
more likely to occur (see Methods). We identified regions of cluster hotspotting across samples
and examined the evolutionary history of those regions looking at both the ages of the genes in
the regions as well as whether or not the regions overlapped evolutionary re-used breakpoint
regions (EBR) or amniote homologous synteny blocks (HSB) [46]. EBRs are regions of the
genome that have been repeatedly subject to structural rearrangement during amniote evolu-
tion. In contrast, HSBs are regions that exhibit not only significant sequence identity, but gene
Table 1. Enrichment score for gene age bins of 500 million years for both COSMIC and OMIM genes.
Age Factor (MY) COSMIC COSMIC Dominant COSMIC Recessive
Scorea p-valuea BSQb Score p-value BSQ Score p-value BSQ
< 500 0.49 9.26x10-5 0.02% 0.56 0.0126 0.02% 0.27 0.00196 0.02%
500–1000 1.32 2.49x10-16 0.02% 1.44 4.38x10-17 0.02% 1.02 0.118 81.32%
1000–1500 1.31 1.05x10-5 0.14% 1.29 2.17x10-4 0.88% 1.32 0.0625 9.96%
1500–2000 0.71 0.298 6.94% 0.59 0.15 2.08% 1.23 0.495 39.48%
2000–2500 0.97 0.907 81.60% 0.93 1 67.42% 0.96 0.931 81.44%
2500–3000 0.93 1 64.70% 0.72 0.438 15.66% 1.4 0.365 23.02%
3000–3500 NA NA NA NA NA NA NA NA NA
> 3500 0.72 0.298 5.40% 0.34 0.00145 0.02% 1.82 0.0395 2.14%
Age Factor (MY) OMIM OMIM Dominant OMIM Recessive
Score p-value BSQ Score p-value BSQ Score p-value BSQ
< 500 0.38 2.90x10-4 0.02% 0.51 0.177 0.30% 0.26 7.51x10-4 0.02%
500–1000 1.32 5.46x10-8 0.12% 1.28 7.54x10-4 4.34% 1.36 4.72x10-5 0.54%
1000–1500 0.91 0.781 44.86% 0.92 0.781 60.84% 0.9 0.781 52.28%
1500–2000 1.18 0.566 39.40% 1.33 0.566 27.66% 1.04 0.781 71.66%
2000–2500 1.18 0.566 37.76% 1.19 0.689 44.62% 1.17 0.689 46.78%
2500–3000 0.95 1 77.96% 0.84 1 57.98% 1.04 0.781 71.64%
3000–3500 NA NA NA NA NA NA NA NA NA
> 3500 1.4 0.126 6.40% 1.12 0.781 56.66% 1.65 0.0873 3.86%
Score indicates the enrichment (> 1) or depletion (< 1) of genes in the age category. Scores that are statistically different from 1 as determined by either the
p-value or BSQ are bolded.
a Enrichment and p-values were computed as indicated in Zeeberg, et al. [41] where the enrichment score is the proportion of genes within the list from the
category divided by the proportion of all human genes that fall into the category. P-values were computer by Fisher’s exact test and then adjusted for
multiple comparisons using the method of Benjamini-Hochenberg as implemented in the p.adjust function of the stats package in R. Scores in bold are have
p-values less than 0.05.
b Bootstrap quantile (BSQ) score: for a given gene set, 10,000 random samples of the same size are taken without replacement from the parental list of
19,756 aged human genes and distribution of ages is calculated for each one. The BSQ score for an age group is the percentile quantile in which the actual
observed frequency value falls for the corresponding age group in the sampling ensemble. Hence, any BSQ value of less than 1% indicates that the
observation is highly unlikely by random sampling.
https://doi.org/10.1371/journal.pone.0176258.t001
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order, across species, and thus represent regions of conserved sequence that have moved as an
intact block through genomic evolution. Based on this, we would predict that genes in EBRs
would be younger than those in HSBs. Previous work demonstrated that SNPs are more preva-
lent in EBRs than in HSBs [46]. Therefore, we might expect that cluster hotspots would co-
localize with EBRs, be less likely in HSBs, and to be enriched in COSMIC genes.
If human genes are classified as either “metazoan” (less than 1000 MY old) or “pre-meta-
zoan” (older than 1000 MY) we found that the set of pre-metazoan genes overlapped with
HSBs and were excluded from EBRs as it might be expected (Table 2). Metazoan genes had the
opposite pattern, being excluded from HSBs and enriched in EBRs. Genes on the COSMIC list
were preferentially located in HSBs and excluded from EBRs.
When considering mutations in normal samples, clustering hotspots co-localized with EBRs
and were excluded from HSBs, independently of whether the analysis included all SNV clusters
or only those that overlapped genes (Table 3). It is very interesting that COSMIC genes were
excluded from hotspot regions in normal samples (Table 4), although genes in that list were
slightly more likely to have clusters compared to other genes (odds ratio OR = 1.389, 95% confi-
dence interval CI = 1.124–1.724, p-value = 0.00192). This suggests that cancer is driven by per-
turbations in parts of the genome that are only slightly more prone to mutation under normal
circumstances. Additionally, cluster hotspots in normal samples overlapped younger genes
(1157 MY in hotspots versus 1380 MY outside of hotspots, t-test = -9.8927, df = 2825.4,
Fig 4. Functional enrichment network of recessive COSMIC cancer genes highlights DNA repair and cell cycle
control. Each node in this network represents a group of functionally related genes as returned in DAVID (gene ontology,
orthology, functional annotations, etc.). The size of the node represents the number of genes in it. Links between nodes
represent gene overlaps between groups, with the width representing the number of genes. Node colors indicate the
general functional categories defined in the legend revealing an additional layer of clustering of gene groups. The number
in the node indicates the group label as given in S2 Table. Further details of these enrichments for each node are
elaborated in S2 Table. For convenience, only nodes with p < 0.002 and FDR < 0.05 are plotted.
https://doi.org/10.1371/journal.pone.0176258.g004
Stress-induced mutation in cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0176258 April 25, 2017 10 / 22
p-value< 2.2x10-16). The genes showing evidence of SNV cluster hotspotting were enriched in
olfactory receptors, glycoproteins, C-type lectins, oxioreductase functions, steroid metabolism/
cytochrome P450 function, serine proteases, oxygen binding, and chromoproteins.
For mutations observed in cancer samples, clustering hotspots typically overlapped with
younger genes (mean gene age in hotspots was 1035 MY old versus 1360 MY old for genes
Fig 5. The genomic distribution of SNV clustering differs between normal and cancer. Circos plot showing distribution of SNV
clustering for chromosomes 1, 3, 13 and 17. Tracks from inside out are: blue, evolutionarily re-used breakpoint regions (EBR); green,
amniote homologous synteny regions (mHSB); orange, hot spots of CM clusters in normal; and red, hot spots of CM clusters in cancer.
Outside text track are symbols for COSMIC genes in their corresponding genomic locations. Dominant genes are in black fonts and
recessive genes are in red font.
https://doi.org/10.1371/journal.pone.0176258.g005
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outside of hotspots, t = -10.412, df = 1007.8, p<2.2.x10-16). Unlike the normal data, the overlap
of hotspots with either HSBs or EBRs depended on the clusters included in the analysis.
Genome-wide, hotspots were excluded from HSBs, but among clusters that overlapped genes,
there was no exclusion or enrichment (Table 5). When we considered only clusters that over-
lap genes, the hotspots were more prevalent in EBRs. However, hotspots were preferentially
excluded from EBRs when we analyzed all clusters across the genome. As with normal data,
COSMIC genes were excluded from cluster hotspots in cancer (Table 4). However, COSMIC
Table 2. Association of gene age and COSMIC gene status with evolutionarily important regions for genome rearrangement.
Gene set Overlap with Odds Ratio 95% Confidence Interval p-value
Metazoan genes (< 1000 MY) HSB 0.6886 0.6503–0.7290 <2.2x10-16
EBR 1.096 1.024–1.1.174 8.342 x 10−3
Pre-metazoan genes (> 1000 MY) HSB 1.452 1.372–1.538 <2.2x10-16
EBR 0.9124 0.8521–0.9769 8.342 x 10−3
COSMIC genes HSB 1.7240 1.409–2.118 3.859 x 10−8
EBR 0.7689 0.5965–0.9814 0.03454
Odds Ratios of >1 indicate enrichment, while odds ratios <1 indicated depletion. HSB, homologous synteny region; EBR, evolutionarily re-used breakpoint
region.
https://doi.org/10.1371/journal.pone.0176258.t002
Table 3. Co-localization of cluster hotspots with evolutionarily important regions for genome rearrangement in normal peripheral blood.
Normal Hotspots in Odds Ratio 95% Confidence Interval p-value
Whole Genome: HSB 0.3053 0.3012–0.3093 <2.2x10-16
EBR 1.135 1.119–1.152 <2.2x10-16
Overlapping Genes: HSB 0.3256 0.3183–0.3331 <2.2x10-16
EBR 1.757 1.715–1.800 <2.2x10-16
The comparison was run looking at private SNVs (determined from trio comparison) clustering across the entire genome as well as clustering that only
overlapped genes. HSB, homologous synteny region; EBR, evolutionarily re-used breakpoint region.
https://doi.org/10.1371/journal.pone.0176258.t003
Table 4. Overlap of COSMIC genes with cluster hotspots (i.e. clustering of clusters) in both normal peripheral blood and tumors based on clusters
that overlap genes.
Category Odds Ratio 95% Confidence Interval p-value
Normal 0.7666 0.7189–0.8172 <2.2x10-16
Cancer 0.3246 0.2897–0.4034 <2.2x10-16
https://doi.org/10.1371/journal.pone.0176258.t004
Table 5. Co-localization of cluster hotspots with evolutionarily important regions for genome rearrangement in cancer genomes.
Cancer Hotspots in Odds Ratio 95% Confidence Interval p-value
Whole Genome: HSB 0.5443 0.532–0.5569 <2.2x10-16
EBR 0.8291 0.8078–0.851 <2.2x10-16
Overlapping Genes: HSB 0.9598 0.9164–1.005 0.08166
EBR 1.4354 1.370–1.504 <2.2x10-16
The comparison was run looking at all clusters as well as only those clusters that overlap genes. HSB, homologous synteny region; EBR, evolutionarily re-
used breakpoint region.
https://doi.org/10.1371/journal.pone.0176258.t005
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genes were more likely to contain clusters by almost 2-fold (OR = 1.873, 95% CI: 1.546–2.272,
p-value = 4.386x10-11) compared to other genes. This suggests that cluster hotspots are driven
by constraints placed on the genome by evolution, and the mechanism of clustering allows
mutation to occur in genomic space that is usually off-limits evolutionarily. The functional
enrichment of genes that overlap clusters in hotspots was also different in cancer. Hotspots in
cancer co-localized with genes that are enriched for extracellular glycoproteins, G-protein cou-
pled receptors especially olfactory receptors, cell-cell adhesion, molecular species intrinsic to
the plasma membrane, Ig- and EGF-like domains, ligand gated ion channels, membrane attack
complex component/perforin, complement 9, cadherin, Sushi domains, potassium channels,
Kazal proteinase inhibitors, fibronectin III, glycosylation, glycoproteins, the machinery to
hydrolize and excrete proteins, and finally MHCI and MHCII.
Interestingly, the hotspot enrichment of young genes was even more evident when we com-
pared the age distribution of mutated genes for both normal and cancer data (Fig 6). In this
case we observed that younger genes are profoundly over-represented in the set of genes that
overlap hotspots despite the fact that that same group of genes is significantly under-repre-
sented for general mutations. In combination with the fact that young genes are markedly
shorter, these observations suggest that the pattern of mutations in young genes is targeted,
possibly under some form of control, and strongly subjected to whatever mechanism generates
cluster hotspots in the genome.
Discussion
Our work highlights the deep evolutionary roots of cancer and the importance of the evolu-
tionary history of the genome in mutational processes driving oncogenesis. Previous studies of
cancer gene ages rely on sparse phylogenetic trees [20,21], and therefore lack the power to
resolve older genetic history. Our investigation is able to probe earlier epochs. Our study
Fig 6. Mutational pattern in young genes is characterized by hot-spotting. (A) Age distribution of all genes mutated in normal
samples data (blue), genes that have neutral level of mutation, as expected from a uniform random distribution (green) and genes in
hotspots (orange). Grey bars represent the age distribution of all human genes. Numbers in legend are the sizes of each gene set. Cross
marks (X) indicate the enrichment in that category is statistically significant according to a bootstrap test (BSQ < 1%, see Table 1).
Boxplots in lower panel show distribution quartiles; black vertical lines are medians, yellow diamonds are means and black dots are
outliers. (B) Equivalent plots for cancer data (ICGC release 19). In both plots when we observe the age distribution of genes involved in
hotspots (orange), a very large proportion of them are very young (less than 500 MY). This suggests that the mutational activity that
produces hot-spotting in the genome is preferentially hitting younger genes in spite of the fact that they are generally under-represented
in the sets of all observed mutations.
https://doi.org/10.1371/journal.pone.0176258.g006
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confirmed the earlier observation of an abundance of genes considered causal in cancer at ages
that span the evolution of multicellularity, but it also revealed that many cancer-causing genes
are much older than previously appreciated. Our analysis shows there is a complex interplay
between the evolutionary history of the genome and the somatic processes shaping the muta-
tional landscape of cancer. We demonstrated that mutational processes in both normal and
cancer cells are more common in evolutionarily young genes and regions of the genome
repeatedly used for structural rearrangement. Mutation was generally excluded from regions
of the genome that have been conserved both in sequence and linear order over large stretches
of DNA through evolutionary time, where genes considered casual in cancer are likely to be
located. Thus, our data demonstrate there are regions of the genome that appear to be hotspots
for mutation and other regions that seem to be protected, probably through a combination of
differential repair mechanisms and protection against mutations. Hotspot regions are more
likely to overlap genes that are evolutionarily young. The genomic instability seen in cancer
has to operate against this pre-existing background, i.e. it is constrained by the evolutionary
history of the genome. On the face of it, we might therefore expect mutational hotspots in can-
cer to a) affect genes known to be frequently and causally mutated in cancer and b) for causally
mutated genes to be evolutionarily young. Intriguingly, our analysis refuted both these predic-
tions: genes that are frequently mutated and causal in cancer are both older and excluded from
these hotspots, although they show a 2-fold enrichment in mutational clustering compared to
other genes. Why?
The answer would seem to lie in the inherent conflict between different levels of selection
that operate in a multicellular organism, where, particularly during development, there is
selection both at the cellular level and at the organismal level. Many of the genes that are causal
in cancer have significant roles in development [47–51]. Selection at the organism level will
remove mutations that might be tolerated at the cell level but cannot be tolerated by the organ-
ism as a whole, effectively protecting the affected genes from hotspotting over time. But since
cells are more likely to survive if mutations happen in a coordinated mutational burst [52],
these genes are not necessarily protected from the mechanisms of cluster formation, and the
resulting mutational clusters can be recovered if the selection pressure moves from both
organismal and cellular levels to only the cellular level. If cancer is a reversion to single-cell
behavior, then the selective pressure on cancer cells move closer to a state dominated by cellu-
lar level selection. It is no surprise then, if in response to an insult or stress, a cancer cell adopts
a survival strategy that might ultimately prove detrimental to the organism. One such strategy
is to reactivate the ancient prokaryotic process of stress-induced mutagenesis, which relies on
low-fidelity breakage-induced replication to generate coordinated clusters of mutational
events that effectively increase the chances of adapting to the stressful environment through
evolution. Activating such a mechanism might also increase the chances of succesful mutation
in genomic regions where the probability of mutation is low because of the evolutionary con-
straints of the genome. These are the regions where many genes important in oncogenesis
reside.
The functional annotation of old recessive cancer genes led to the hypothesis that stress-
induced mutation plays a role in genomic instability in cancer and the mutational clusters seen
in cancer represent the molecular signature of a conserved stress-induced mutagenesis
response. The genes in humans that are orthologous to the error-prone polymerases that
mechanistically drive the stress-induced mutation response in bacteria have become special-
ized DNA polymerases for translesion synthesis (TLS) employed during replication by-pass of
DNA damage [42]. These polymerases recognize specific types of DNA damage and faithfully
replicate the damaged DNA (for example incorporating a C when encountering O-methyl-
guanine) but exhibit orders of magnitude less fidelity against undamaged DNA [42]. Thus, for
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DNA damage incurred or persisting into S-phase, these so-called error-prone DNA polymer-
ases will be employed during replication leading to an overall up-tick in single base mutations.
In normal cells, the tightly controlled regulation of DNA repair with cell cycle prevents the
propagation of the vast majority of these TLS mutations into the next cell division by halting
the cell cycle and allowing time for mismatch recognition and repair, or in extreme cases, gen-
erating an apoptotic response, at least in somatic cell lineages.
In bacteria the stress-induced mutation response leaves behind a molecular signature that
can be detected in the form of SNV clusters around DSBs [44]. We observed analogous clusters
in the whole genome sequences of human tumors as well as in normal peripheral blood, the
latter reflecting the de novo mutations arising during meiosis or early embryonic development.
These clusters are not randomly distributed across the genome, with a distribution that differs
according to whether they come from normal or cancer samples, further supporting that idea
that cancer is mutating a different subset of genomic space compared to normal tissue. The
data from normal samples imply that there may be a developmental regulation of mutational
bursts outside of the well-recognized somatic hyper-mutation processes in the immune sys-
tem. This is supported by recent work on the rate and timing of mutations in the germline
[53]. Additionally, recent work by Francioli et al suggests that there is a role of TLS in the gen-
eration of de novo mutations in the germline [54]. In their study, they observed that clusters of
mutations were enriched in C> G transversions but not in the sequence contexts recognized
by APOBEC relative to non-clustered mutations. They postulate that they are the result of
error-prone TLS [54].
In cancer, the role of TLS in the generation of genomic instability has been recognized but
attributed to oncogene-induced replication-stress, not the induction of a programmed muta-
tional response [55]. The abrogation of the link between DNA damage and cell cycle by elimi-
nating efficient activation of cell cycle checkpoints or altering the function of some but not all
DNA repair pathways, leads to persistent DNA damage, TLS employment, and an increase in
TLS introduced errors that survive to the next round of replication. Recent work in yeast on
mutagenic breakage-induced replication demonstrated both a reliance on TLS as well as a
resulting mutation pattern that resembles the phenomenon of kataegis seen in cancer [56,57],
suggesting an additional mechanism by which TLS could be involved in the generation of
mutational clusters. The decrease in DNA repair capacity of the cancer cell per unit time may
also play into the role of APOBEC in generating clusters of mutations in cancer [35,58]
through increasing the amount of single-single strand DNA substrates available in the genome.
However, only roughly half of the clusters identified by Roberts, et al. had a sequence context
suggestive of APOBEC or AID activity [35]. Additionally, TLS is thought to play a role in the
C> G transversions in APOBEC driven clusters through by-pass of abasic sites as a result
UNG driven repair of the resulting uracil.
Altogether our results on the age of the recessive genes, the homology to the proteins
involved in stress-induced mutation in bacteria to non-mutated genes in DNA repair and cell
cycle pathways in humans, and the observation of the molecular signature of stress-induced
mutation in human tumors are strong evidence for the restoration of a stress-induced muta-
tional response in somatic cells. Our analysis supports the idea that the stress induced muta-
tional program remains functional but has become cell-lineage constrained. Based on our
analysis we propose that, in multi-cellular organisms, the restriction of mutational processes
that promote evolution in the germline and the immune system was brought about by re-wir-
ing the input for the mutational response to be a developmental signal, rather than a cellular
stress signal. This in turn suggests epigenetic control. A variety of conditions, such as chronic
inflammation, may lead to microenvironments where the epigenetic regulation that keeps the
mutational program under developmental and lineage control are altered, allowing somatic
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cells inappropriate access to a stress-induced mutational response. Thus, we propose stressed-
induced mutation as a hallmark of cancer reflected by genomic instability.
Our results have important implications for the clinical management of cancer. There is
already evidence that TLS polymerase expression contributes to both intrinsic and acquired
resistance to genotoxic therapies [59–67]. However, the mechanism of stress-induced muta-
genesis would predict a role for TLS activity in resistance to a wide range of therapies, includ-
ing targeted therapies. The current paradigm for understanding therapeutic resistance
contends that intracellular heterogeneity leads to multiple, clonal subpopulations with a priori
different susceptibilities to treatment. Treatment creates a bottleneck resulting in clonal selec-
tion. This selection is inferred from the observation that mutational events that have become
fixed in the population may dramatically alter their frequency following treatment [68–70].
The surviving clones then re-establish their diversity after the fact because of ongoing instabil-
ity. Resistance to therapy arises either because it existed a priori and survives the clonal sweep
or it develops as the population re-diversifies at the cellular level. However, the phenotype of
stress-induced mutation would predict that the bottleneck itself is the primary driver of inter-
cellular genomic diversity leading to the acquisition of resistance. Furthermore, both clonal
selection and regeneration of intercellular diversity occur simultaneously. If we accept that
tumor formation occurs over years in most cases, then the rapid and almost universal acquisi-
tion of resistance to inhibitors of the BRAF V600E mutation is suggestive that this is indeed
occurring [71]. The rapidity with which resistance to an effective therapy is acquired would
likely depend on how robustly a given tumor has activated the stress-induced mutation pro-
gram. Treatment dynamics are likely to be very important in minimizing the impact of stress-
induced mutation on tumor progression, with both the intensity and duration of exposure
playing a role. We hypothesize that there is a threshold effect of stress induction below which
tumor cell fitness is compromised but elevated mutation is not induced. Thus, lower doses
given more frequently may be more effective at controlling cancer progression in the long run.
This is supported by a recent study showing that intermittent dosing of patient-derived xeno-
grafts of BRAF V600E mutant melanoma results in a failure to reach lethal drug resistance,
even when the cumulative dose meets or exceeds that received on a continuous dosing regimen
where all tumors acquired lethal drug resistance [72]. Similarly, in newly diagnosed multiple
myeloma, patient outcomes were the same or better with lower toxicities on a regimen of
Lenalidomide plus low-dose dexamethasone [73]. In preclinical models of breast cancer, adap-
tive therapeutic treatment, where an initial large dose of paclitaxel is used to drive the tumor
growth rate to plateau followed by regular doses that were then adjusted based on the change
in tumor size, led to long term stabilization of tumor growth and increased survival [74]. This
suggests a fundamental switch in treatment paradigm from maximum tolerable dose to mini-
mum efficacious dose and the use of metronomic or adaptive therapy strategies, and from
‘cure’ to management of cancer as a chronic disease.
In conclusion, our analysis suggests that the observed phenotype of evolvability in cancer is
driven by re-activation of an evolutionarily ancient stress-induced mutational response.
Understanding the parameters of this response will be key to maximizing the effectiveness of
cancer treatment.
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